Clinical Trial Update: Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing TDF/FTC + raltegravir versus TDF/FTC + efavirenz in HIV-1-infected women has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Isentress (Raltegravir)
• Sustiva (efavirenz)
• TRUVADA (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE)

Snippet

Sponsor: Rush University Medical Center | Conditions: HIV-1 Infections | Phase 3 | Status: WITHDRAWN